Table 4.
Risk factors for tumor recurrence and death in the combined hepatocellular carcinoma and cholangiocarcinoma group
|
Tumor recurrence
|
Death
|
||||||
|
|
OR
|
95%CI
|
P value
|
|
OR
|
95%CI
|
P value
|
| Univariate | Univariate | ||||||
| Sex (male) | 4.763 | 1.155-19.640 | 0.031 | Sex (male) | 6.464 | 0.883-47.317 | 0.066 |
| Recipient age | 0.999 | 0.958-1.041 | 0.957 | Recipient age | 1.005 | 0.957-1.057 | 0.833 |
| Locoregional therapy before LT | 1.724 | 0.907-3.274 | 0.096 | Locoregional therapy before LT | 1.924 | 0.891-4.153 | 0.096 |
| TACE before LT | 1.826 | 0.989-3.371 | 0.054 | TACE before LT | 2.188 | 1.039-4.609 | 0.039 |
| Liver resection before LT | 2.594 | 1.387-4.852 | 0.003 | Liver resection before LT | 0.941 | 0.365-2.428 | 0.9 |
| RFA before LT | 1.616 | 0.781-3.340 | 0.196 | RFA before LT | 2.284 | 1.025-5.090 | 0.043 |
| Radiation therapy before LT | 0.718 | 0.174-2.962 | 0.646 | Radiation therapy before LT | 0.654 | 0.089-4.813 | 0.677 |
| Number of locoregional therapies before LT > 3 | 1.068 | 1.002-1.138 | 0.043 | Number of locoregional therapies before LT > 3 | 1.733 | 0.865-3.473 | 0.121 |
| MELD | 0.993 | 0.950-1.038 | 0.742 | MELD | 1.012 | 0.965-1.063 | 0.617 |
| Type of LT (DDLT) | 0.934 | 0.397-2.198 | 0.875 | Type of LT (DDLT) | 1.518 | 0.626-3.680 | 0.365 |
| ABO-incompatibility | 1.563 | 0.618-3.952 | 0.345 | ABO-incompatibility | 0.79 | 0.189-3.297 | 0.746 |
| Tumor size > 3cm | 3.013 | 1.707-5.317 | < 0.001 | Tumor size > 3 cm | 3.462 | 1.740-6.888 | < 0.001 |
| Tumor number > 3 | 1.35 | 0.723-2.520 | 0.346 | Tumor number > 3 | 1.463 | 0.694-3.084 | 0.318 |
| Milan criteria (beyond) | 2.495 | 1.403-4.436 | 0.002 | Milan criteria (beyond) | 2.813 | 1.395-5.670 | 0.004 |
| Tumor grade 3 or 4 | 1.465 | 0.809-2.651 | 0.208 | Tumor grade 3 or 4 | 1.229 | 0.586-2.580 | 0.585 |
| Microvascular invasion | 2.417 | 1.360-4.297 | 0.003 | Microvascular invasion | 2.28 | 1.153-4.507 | 0.018 |
| PVTT | 1.416 | 0.661-3.032 | 0.37 | PVTT | 1.302 | 0.502-3.376 | 0.587 |
| BDTT | 0.047 | 0.000-36.844 | 0.368 | BDTT | 0.048 | 0.000-333.805 | 0.5 |
| Intrahepatic metastasis | 1.357 | 0.676-2.722 | 0.39 | Intrahepatic metastasis | 1.182 | 0.515-2.716 | 0.693 |
| Multicentric occurrence | 1.148 | 0.607-2.170 | 0.671 | Multicentric occurrence | 1.125 | 0.526-2.403 | 0.762 |
| Encapsulation | 1.269 | 0.582-2.766 | 0.549 | Encapsulation | 0.952 | 0.367-2.471 | 0.92 |
| Tumor necrosis | 2.361 | 1.302-4.281 | 0.005 | Tumor necrosis | 3.22 | 1.531-6.773 | 0.002 |
| Dominant type (CC) | 0.995 | 0.495-2.003 | 0.989 | Dominant type (CC) | 0.823 | 0.375-1.805 | 0.627 |
| Lymph node metastasis | 13.954 | 3.065-63.526 | 0.001 | Lymph node metastasis | 24.719 | 4.683-130.472 | < 0.001 |
| AFP > 20 ng/mL | 1.563 | 0.880-2.777 | 0.128 | AFP > 20 ng/mL | 1.527 | 0.769-3.033 | 0.226 |
| PIVKA-II > 40 mAU/mL | 1.067 | 0.576-1.975 | 0.837 | PIVKA-II > 40 mAU/mL | 1.762 | 0.865-3.589 | 0.118 |
| Multivariate | Multivariate | ||||||
| Number of locoregional therapies before LT > 3 | 1.813 | 1.012-3.248 | 0.046 | Tumor size > 3 cm | 4.591 | 1.851-11.390 | 0.001 |
| Tumor size > 3 cm | 2.378 | 1.321-4.280 | 0.004 | ||||
| Lymph node metastasis | 8.585 | 1.822-40.453 | 0.007 | ||||
OR: Odds ratio; CI: Confidence interval; LT: Liver transplantation; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; MELD: Model for end-stage liver disease; DDLT: Deceased donor liver transplantation; PVTT: Portal vein tumor thrombosis; BDTT: Bile duct tumor thrombosis; CC: Cholangiocarcinoma; AFP: Alpha-fetoprotein; PIVKA-II: Prothrombin-induced by vitamin K absence-II.